102 related articles for article (PubMed ID: 12050919)
1. [LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
Heinzl S
Med Monatsschr Pharm; 2002 May; 25(5):149. PubMed ID: 12050919
[No Abstract] [Full Text] [Related]
2. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
3. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
[TBL] [Abstract][Full Text] [Related]
4. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
[No Abstract] [Full Text] [Related]
5. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
7. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Fossum E; Olsen MH; Høieggen A; Wachtell K; Reims HM; Ibsen H; Julius S; Kjeldsen SE
J Hum Hypertens; 2004 Jun; 18(6):375-80. PubMed ID: 15057253
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
9. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
[TBL] [Abstract][Full Text] [Related]
10. [LIFE study proves preventive action. With losartan to do even more against stroke].
Baumgart P
MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
[No Abstract] [Full Text] [Related]
11. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
12. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
14. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
[No Abstract] [Full Text] [Related]
15. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
16. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Reims HM; Kjeldsen SE; Brady WE; Dahlöf B; Devereux RB; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hum Hypertens; 2004 Jun; 18(6):381-9. PubMed ID: 15103313
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
[TBL] [Abstract][Full Text] [Related]
18. The LIFE Trial in 2004.
Beevers DG
J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
[No Abstract] [Full Text] [Related]
19. LIFE: losartan versus atenolol.
Chong AY; Lip GY
Lancet; 2003 Oct; 362(9393):1416. PubMed ID: 14585648
[No Abstract] [Full Text] [Related]
20. [Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
MMW Fortschr Med; 2004 Apr; 146(18):55. PubMed ID: 15366474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
